Barclays initiated coverage of Astrana Health (ASTH) with an Equal Weight rating and $36 price target The company is well positioned to capture improving rates in the government sector, but the scale and complexity of the pending Prospect deal tempers excitement, the analyst tells investors in a research note. The firm believes the near-term execution risks are real given the scale. As such, it comes out on the sidelines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health Appoints New Chief Accounting Officer
- Astrana Health price target lowered to $46 from $50 at Truist
- Astrana Health Highlights Strategic Acquisition Plans
- Astrana Health: Strategic Growth and Undervalued Opportunities Reinforce Buy Rating
- Astrana Health price target lowered to $49 from $55 at BofA